News & Analysis on Contract Research, Manufacturing & Clinical Trials
DCAT WEEK '17
CordenPharma: Closing a market gap
By Melissa Fassbender
- Last updated on
Mimoun Ayoub, PhD, director global peptides, oligonucleotides, lipids, carbohydrates and injectable platforms said CordenPharma has invested heavily in expanding its capabilities and capacity in highly potent products.
Recently, it made its first entry into oligonucleotides, a move triggered by a “very rich pipeline.”
“There is not enough capacity to respond to the market needs,” Ayoub said. “So, CordenPharma has decided to help the market close that gap.”
Ayoub described Oligonucleotide APIs as “a central piece that was missing.” Though, “we are closing that gap now,” he said, adding that the only piece now missing is upstream processing – which will be added in two phases expected to be finalized by the fourth quarter of 2017.
The company is also investing in aseptic filling and adding two high-speed lines – one for prefilled syringes and another for vials.
“We are also adding Lyophilization capabilities,” added Ayoub, “All of this will be completed before the end of the year.”